Equivalent of Form PTO/SB/08a (11-08)

Substitute for form 1449/PTO

1

Sheet

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

Complete i	February 18, 2004 Inventor MONTERO-JULIAN, Felix A. 1644 Inme DIBRINO, Marianne NMN 2512.0210001/KWM/ROM
Application Number	10/782,664
Filing Date	February 18, 2004
First Named Inventor	MONTERO-JULIAN, Felix A.
Art Unit	1644
Examiner Name	DIBRINO, Marianne NMN
Au Dada North	2512.0210001/KWM/ROM
Attorney Docket Number	(2052-183-NONP)

			U.S. PATENT DOC	CUMENTS	
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
Initials No. Number-Kind Code ^{2 (If Known)}	MIMI-DD-1111	Applicant of Cited Document	or Relevant Figures Appear		
	-				

	***	Fo	REIGN PATENT DO	OCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	FP17	WO 92/07952 A1	05-14-1992	Immulogic Pharmaceutical Corporation; Merck & Co., Inc.		
	FP18	JP 4-505401	09-24-1992	Institut National de la Sante et de la Recherche Medicale		Abs
	FP19	JP 6-506056	07-07-1994	Immulogic Pharmaceutical Corporation; Merck & Co., Inc.		Abs
	FP20	WO 02/072631 A2	09-19-2002	Dako A/S; Dynal Biotech ASA		

1026465 1.doc

Examiner	Date	
Signature	Consi	dered

English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute for form	1449/PT	О		Con	iplete if Known
THIRD SUPPLEMENTAL			TAI	Application Number	10/782,664
				Filing Date	February 18, 2004
	NFORMATION DISCLOSURE		First Named Inventor	MONTERO-JULIAN, Felix A.	
STATEMENT BY APPLICANT (Use as many sheets as necessary)		Art Unit	1644		
		Examiner Name	DIBRINO, Marianne NMN		
Sheet	1	of	1	Attorney Docket Number	2512.0210001/KWM/ROM (2052-183-NONP)

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	NPL55	ALEXANDER, J., et al., "Derivation of HLA-A 11/K ^b Transgenic Mice: Functional CTL Repertoire and Recognition of Human A11-Restricted CTL Epitopes," <i>J. Immunology</i> 159:4753-4761, The American Association of Immunologists, Bethesda, MD USA (1997)	
	NPL56	CHERSI, A., et al., "Polystyrene Beads Coated with Antibodies Directed to HLA Class I Intracytoplasmic Domain: the Use in Quantitative Measurement of Peptide-HLA Class I Binding by Flow Cytometry", Hum. Immunol. 61:1298-1306, American Society for Histocompatibility and Immunogenetics, Mt. Laurel, NJ USA (2000)	
	NPL57	English language abstract of WO 91/12332 A1	
	NPL58	DENKBERG, G., et al., "Critical Role for CD8 in Binding of MHC Tetramers to TCR: CD8 Antibodies Block Specific Binding of Human Tumor-Specific MHC-Peptide Tetramers to TCR," <i>The Journal of Immunology 167</i> :270-276, The American Association of Immunologists, Bethesda, MD USA (July 2001)	
	NPL59	DENKBERG, G., et al., "Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens," Eur. J. Immunol. 30:3522-3532, Wiley-VCH Verlag GmbH, Wiley, Hoboken, NJ USA (2000)	
	NPL60	DENKBERG, G., et al., "Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC restricted T cell receptor-like specificity," PNAS 99:9421-9426, Proceedings of the National Academy of Sciences, Washington, DC USA (2002)	

1026464_1.doc Date Examiner Considered Signature

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in its in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.